Latest IPO Information

Mahamaya Lifesciences Ltd. IPO

IPO Date: Nov 11 to Nov 13 2025

Listing Date: Nov 18 2025

Objective

a. Purchase of Equipment for existing Formulation plantb. Funding capital expenditure towards setting up of a new Technical manufacturing plant.c. Construction of Warehouse Building and Purchase of Machineryd. Funding working capital requirement of our Companye. General Corporate purposes

IPO Details

Face Value ₹ 10.00 Per Share
Issue Size ₹ 47.81 - 50.47 Cr
Price Band ₹ 108.00 - ₹ 114.00 Per Share
Market LOT 2400 shares
Issue Type Book building

About Company

Our company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). We began our journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. We imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration we marketed .... these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs. Read More
Address

Unit No: D P T – 033 Ground Floor, Plot No: 79 – 80, Dlf Prime Tower F – Block, Okhla, Phase – 1

City

New Delhi

State

Delhi

Pincode

110020

Phone

011-46561474

Email

cs@mahamayalifesciences.com

Website

https://www.mahamayalifesciences.com/home

About IPO

Listed At BSE
Lead Manager Oneview Corporate Advisors Pvt Ltd.
Promoters
Krishnamurthy Ganesan
Prashant Krishnamurthy
Lalitha Krishnamurthy

Promoter's Holding

Registrar

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

040 - 67162222/18003094001
einward.ris@kfintech.com
www.kfintech.com

Latest News

Sep
30
2026
EQUITY Posted on Sep 30th 2026

Mahamaya Lifesciences informs about change in management

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of the said Regulations, Mahamaya Lifesciences has informed that the members of the Company, based on the recommendations of Board of Directors & Nomination and Remuneration Committee approved the following resolutions at their meeting held on Tuesday, September 29, 2026, at 11:00 AM: Appointment of Dr. Bhagirath Choudhary as Independent Director, Re-appointment of Dr. Charudatta Digambar Mayee as Independent Director, Re-appointment of Gopal Krishna Raju as Independent Director, Re-designation of Krishnamurthy Ganesan as Chairman, and Re-designation of Prashant Krishnamurthy as Managing Director.
The above information is a part of company’s filings submitted to BSE.
Read More
Oct
12
2026
ECONOMY Posted on Oct 12th 2026

Finance Minister discusses business cooperation, trade ties with Singapore

With a view to expanding bilateral ties, Finance Minister Nirmala Sitharaman met Singapore Business Federation (SBF) Chairman Mark Lee in Singapore on October 10, 2026, to discuss strengthening business engagement between the two countries through targeted business matching, trade delegations and cooperation in key sectors.

The Finance Ministry said the discussions focused on facilitating visits by Singaporean business delegations to India to enable meaningful interactions with Indian businesses and state governments, thereby expanding bilateral commercial opportunities. It added that Singapore’s ASEAN chairmanship in 2027 offers an opportunity to build further momentum in bilateral and regional economic cooperation. During the meeting, SBF highlighted potential areas of collaboration, including semiconductor supply chains, maintenance, repair and overhaul (MRO), food security and food processing.

Sitharaman also met Monetary Authority of Singapore (MAS) Deputy Managing Director Leong Sing Chiong. The MAS team presented its approach to tokenisation, including how the authority is fostering the development of the digital asset ecosystem, the ministry said in a separate post.

The ministry said the bilateral discussions explored potential efficiency gains from tokenisation, the importance of interoperability and trusted settlement arrangements, and the associated regulatory challenges. It added that both sides reaffirmed their commitment to working closely together on these emerging technologies.

Read More
Oct
12
2026
EQUITY Posted on Oct 12th 2026

Mahasagar Travels informs about compliance certificate

In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Mahasagar Travels has informed that it enclosed a copy of compliance certificate for the quarter ended September 30, 2026 received from RTA - MUFG Intime India.
The above information is a part of company’s filings submitted to BSE. 
Read More
Oct
11
2026
COMPANY Posted on Oct 11th 2026

Premier Polyfilm - Quaterly Results

The sales for the September 2026 quarter moved up 38.10% to Rs. 1161.80 millions as compared to Rs. 841.30 millions during the corresponding quarter last year.Profit saw a slight increase of 22.47%to Rs. 98.10  millions from Rs. 80.10 millions.Operating profit for the quarter ended September 2026 rose to 145.30 millions as compared to 122.90 millions of corresponding quarter ended September 2025.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 1161.80 841.30 38.10 2168.30 1591.00 36.29 3412.60 3046.40 12.02
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 145.30 122.90 18.23 280.50 219.40 27.85 483.00 408.60 18.21
Interest 2.40 1.30 84.62 4.40 3.70 18.92 8.10 11.60 -30.17
PBDT 142.90 121.60 17.52 276.10 215.70 28.00 474.90 397.00 19.62
Depreciation 11.80 11.60 1.72 23.60 23.30 1.29 46.90 50.70 -7.50
PBT 131.10 110.00 19.18 252.50 192.40 31.24 428.00 346.30 23.59
TAX 33.00 29.90 10.37 63.60 52.30 21.61 109.20 86.30 26.54
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 1.30 -0.60 -316.67
PAT 98.10 80.10 22.47 188.90 140.10 34.83 318.80 260.00 22.62
Equity 105.90 105.90 0.00 105.90 105.90 0.00 105.90 105.90 0.00
PBIDTM(%) 12.51 14.61 -14.39 12.94 13.79 -6.19 14.15 13.41 5.52
Read More
Oct
11
2026
COMPANY Posted on Oct 11th 2026

Avenue Supermarts - Quaterly Results

The Revenue for the quarter ended  September 2026 of Rs. 192061.80 millions grew by 18.42 % from Rs. 162187.90 millions.Modest increase of 7.64% in the Net Profit was reported from. 7465.50 millions to Rs. 8036.00  millions.Operating Profit saw a handsome growth to 14264.60 millions from 12628.80 millions in the quarter ended September 2026.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 192061.80 162187.90 18.42 375496.70 321509.10 16.79 669680.30 577898.10 15.88
Other Income 232.70 329.20 -29.31 610.30 670.50 -8.98 1280.20 1740.20 -26.43
PBIDT 14264.60 12628.80 12.95 29911.30 26103.30 14.59 53832.40 47167.40 14.13
Interest 595.50 318.40 87.03 1101.50 584.60 88.42 1299.30 577.50 124.99
PBDT 13669.10 12310.40 11.04 28809.80 25518.70 12.90 52533.10 46589.90 12.76
Depreciation 2870.40 2282.20 25.77 5491.10 4378.00 25.42 9348.10 7758.20 20.49
PBT 10798.70 10028.20 7.68 23318.70 21140.70 10.30 43185.00 38831.70 11.21
TAX 2762.70 2562.70 7.80 5925.00 5377.90 10.17 10945.70 9559.90 14.50
Deferred Tax 29.20 36.70 -20.44 98.20 67.40 45.70 93.40 211.10 -55.76
PAT 8036.00 7465.50 7.64 17393.70 15762.80 10.35 32239.30 29271.80 10.14
Equity 6522.50 6507.30 0.23 6522.50 6507.30 0.23 6519.60 6507.30 0.19
PBIDTM(%) 7.43 7.79 -4.62 7.97 8.12 -1.89 8.04 8.16 -1.51
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the issue size of Mahamaya Lifesciences Ltd. IPO?

The issue size of Mahamaya Lifesciences Ltd. IPO is ₹47.81 - 50.47 crore.

The Mahamaya Lifesciences Ltd. IPO opens for subscription on 2025-11-11 and closes on 2025-11-13.

The price range of Mahamaya Lifesciences Ltd. IPO is ₹108.00 to ₹114.00.

The lot size of Mahamaya Lifesciences Ltd. IPO is 2400 shares.

The registrar of Mahamaya Lifesciences Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).

Mahamaya Lifesciences Ltd. IPO will be listed on BSE .

You will typically receive a confirmation message or notification from your broker or trading platform shortly after placing your IPO order. This confirms that your application has been submitted successfully. You can also check the order status in the IPO section of your trading account or app.

Apply early with valid UPI and PAN before 2025-11-13 to increase your chances.

The listing date of Mahamaya Lifesciences Ltd. IPO is 2025-11-18.

An Initial Public Offering (IPO) is when a private company sells shares to the public for the first time, enabling investors to purchase these shares and gain partial ownership in the business. For instance, if a well-known tech firm wants to grow and requires additional funds, it might choose to go public through an IPO. During this process, investors can buy shares, and the company’s stock starts trading on the stock exchange on the day of the IPO listing.

Investors can apply for an IPO through their bank or brokerage account. Many trading platforms have a specific section for IPOs where users can submit their applications online.

The primary market is where shares are offered to the public for the first time via an IPO. After the IPO, shares are traded on the secondary market (stock exchange), where existing shareholders can sell to new buyers.

Investing in an IPO offers the opportunity to become an early investor in companies with high growth potential, at a price which may be lower than their post-listing market value. It provides a chance to participate in the company's growth journey from its early stages. However, IPO investments also come with inherent risks, such as market volatility and uncertainties about the company's future performance.

The price of an IPO is established through a systematic process known as "book building." In this method, investors bid within a given price range, and the final price is set based on demand and market conditions. Several factors play a crucial role in determining the IPO price, including:

Past Financial Performance: Evaluating the company's revenue, profits, and financial stability over time

Growth Potential: Assessing future prospects based on the company's business model and market opportunities

Industry Peers: Comparing valuation metrics with similar companies in the same sector

Larger Industry Picture: Analysing overall industry trends and economic conditions that could impact the company's performance

The lock-in period for IPO shares refers to a duration during which specific investors are restricted from selling their shares post-listing. This period varies based on the type of investor:

Promoters: The lock-in period for promoters ranges from 6 months to 18 months, ensuring their commitment to the company's long-term growth

Anchor Investors: Typically, anchor investors face a shorter lock-in period of 30 to 90 days, depending on regulatory norms and the specific IPO

IPOs can be volatile and may not perform as expected in the short term. Investors risk losing capital if the stock price drops after listing, especially if the company does not meet its growth projections.

Information on upcoming IPOs is often available through brokerage platforms, financial news sites, and regulatory bodies like SEBI, which publishes details on companies going public. You can also get these details under the upcoming IPO section on Bajaj Markets.

Eligibility for an IPO typically includes:

Retail Investors: Individuals who invest in smaller amounts, usually under the “retail investor” category, with certain limits

Qualified Institutional Buyers (QIBs): Entities like mutual funds, banks, and insurance companies, who invest large sums

Non-Institutional Investors (NIIs): High-net-worth individuals or entities investing above the retail threshold

Investors must have a Demat and trading account to apply, and in some cases, certain financial or residency qualifications may apply depending on local regulations.

SME (Small and Medium Enterprise) IPOs generally carry higher risk but may provide significant growth potential. Investors should research the company’s stability, financials, and sector risks, as SME stocks can be more volatile compared to large-cap companies.

View More

Invalid Mobile Number

Invalid Full Name

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore